WRAL Tech Wire

OxyBio strikes supply, manufacturing deal for skin product

By WRAL Tech Wire

The agreement gives Lausanne, Switzerland-based Valor the exclusive right to sell, import, export, distribute, package label and otherwise commercialize Dermacyte. Before reaching the agreement, Oxygen had handled Dermacyte manufacturing and distribution. Dermacyte is a skin care product that uses Oxygen’s technology to enhance the delivery of oxygen to damaged tissues.

Valor must pay Morrisville-based Oxygen a non-refundable license fee as well as a royalty on Dermacyte sales. Oxygen said that the agreement leaves the company free to focus on its drug development work. Oxygen’s lead program is the experierimental therapy Oxycyte, which is in clinical trials as a potential traumatic brain injury treatment.

WRAL Tech Wire any time: Twitter, Facebook

Please log in or register to view WRALTechWire Insider content

To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

 1 Year Membership - 49.99 per year. Includes FREE unlimited access to online content, archives and discounts from Insider Partners. For less than $1 a week receive more than $900 in value.

 Monthly Membership - 4.99 per month. Includes FREE unlimited access every 30 days to online content only.

 Day Pass - 0.99 per day. Includes FREE unlimited access for 24 hours to online content only.

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…